CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,011 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01998737
NCT01998737N/ACompleted

Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX

Bone Index Finland Ltd·observational·Posted Dec 2, 2013·Updated Sep 21, 2017

In Brief

An observational study for Osteoporosis. Completed, enrolled 1,011 participants across 6 sites.

Detailed Summary

Osteoporosis is a disease that leads to impaired skeletal strength and increased fracture risk. Among 200 million osteoporotic patients (Tarantino, Cannata et al. 2007) most are diagnosed only after several fractures. Furthermore, the progressively aging population will increase the prevalence of osteoporosis. It is estimated that over 75% of osteoporotic patients are not diagnosed and does not receive treatment for their condition. In this study we aim to investigate the strength of Density Index (DI) for prediction of proximal femur and lumbar spine BMD as well as determining the diagnostic thresholds for DI for osteoporosis diagnostics by using the International Society for Clinical Densitometry guidelines. In addition we aim to investigate how many additional women would be identified for osteoporosis diagnosis/ treatment based on adding FRAX to Bindex versus adding FRAX to DXA. The investigators will start and organize a multicenter study in 5 osteoporosis clinics in Suomen Terveystalo Healthcare Service Company in Finland. A total of 1100 postmenopausal women (age 50 -79 years) will be measured with both axial DXA and Bindex. In addition, the FRAX questioinnaire will be asked from everybody attending the study. Clinical hypotheses: 1. Cortical bone thickness is decreased in osteoporosis. 2. Patient age, weight and height are related to BMD status and therefore are needed in BMD estimation (Density Index). 3. Ultrasound is a safe method in osteoporosis screening and diagnostics for osteoporosis. 4. Fracture risk factors (FRAX) and point-of-care bone density measurement together have significantly higher sensitivity and specificity for osteoporosis/treatment decisions than one method alone.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesFinland

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2, 2013
Enrollment StartNov 1, 2013
Primary CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.6 years ago